We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AMS:BMEAmadeus IT Group SA Class A Analysis

Data as of 2026-06-05 - not real-time

$1.38

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

American Shared Hospital Services is trading around $1.38, well below its 52‑week low of $1.25 and far beneath the calculated resistance of $2.13, giving it a potential upside of nearly 190% based on the upside/downside metric. The forward P/E of 3.45 is dramatically lower than the industry average of 27.7, while the price‑to‑book of 0.38 and price‑to‑sales of 0.31 suggest the stock is deeply undervalued. Revenue grew 15.9% YoY driven by expansion of direct patient services, but operating and profit margins remain negative, and cash flow generation is currently zero, highlighting ongoing profitability challenges. The balance sheet shows a high debt load (over $21 M) relative to a market cap under $10 M, resulting in a debt‑to‑equity ratio above 78, which adds financial stress despite the attractive valuation multiples.
Technical indicators point to a neutral price trend, with the 20‑day SMA (1.53) above the 50‑day SMA (1.51) yet the market price sitting well below both averages, and the MACD histogram is bearish. RSI at 43 indicates no extreme overbought or oversold condition, while decreasing volume and a beta near zero suggest limited price momentum and low correlation to broader markets. High 30‑day volatility (over 100%) and limited liquidity amplify short‑term risk, but the strong revenue growth narrative and substantial valuation gap support a longer‑run buying case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and price below short‑term moving averages
  • Decreasing volume and high short‑term volatility
  • Negative operating margins limiting immediate upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong 15.9% YoY revenue growth from direct patient services
  • Significant valuation discount vs industry (forward P/E 3.45 vs 27.7)
  • Potential upside of ~190% to target price of $4

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Transition to owning and operating treatment facilities expanding revenue base
  • Undervalued balance sheet metrics despite high debt
  • Long‑run demand for advanced radiation therapy technology

Key Metrics & Analysis

Financial Health

Revenue Growth15.90%
Profit Margin-5.30%
P/E Ratio3.5
Debt/Equity78.27
P/B Ratio0.4
Industry P/E27.7

Technical Analysis

TrendNeutral
RSI43.6
Support$1.32
Resistance$2.13
MA 20$1.53
MA 50$1.51
MA 200$2.05
MACDBearish
VolumeDecreasing
Fear & Greed Index93.93

Valuation

Target Price$4.00
Upside/Downside189.86%
GradeUndervalued
TypeValue

Risk Assessment

Beta-0.07
Volatility101.26%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.